請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72867
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 莊雅惠(Ya-Hui Chuang) | |
dc.contributor.author | Chih-Yu Liu | en |
dc.contributor.author | 劉芝宇 | zh_TW |
dc.date.accessioned | 2021-06-17T07:08:37Z | - |
dc.date.available | 2024-08-26 | |
dc.date.copyright | 2019-08-26 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-07-23 | |
dc.identifier.citation | 1. Kaplan MM, Gershwin MEJNEJoM. Primary biliary cirrhosis. 2005;353:1261-1273.
2. Lu M, Zhou Y, Haller IV, et al. Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment. Clin Gastroenterol Hepatol 2018;16:1342-1350 e1. 3. Kim WR, Lindor KD, Locke GR, 3rd, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000;119:1631-6. 4. Invernizzi P, Selmi C, Mackay IR, et al. From bases to basis: linking genetics to causation in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2005;3:401-10. 5. Selmi C, Mayo MJ, Bach N, et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology 2004;127:485-92. 6. Hirschfield GM, Liu X, Xu C, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009;360:2544-55. 7. Smyk D, Rigopoulou EI, Bizzaro N, et al. Hair dyes as a risk for autoimmunity: from systemic lupus erythematosus to primary biliary cirrhosis. Auto Immun Highlights 2013;4:1-9. 8. Zein CO, Beatty K, Post AB, et al. Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment. Hepatology 2006;44:1564-71. 9. Ormarsdottir S, Mallmin H, Naessen T, et al. An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis. J Intern Med 2004;256:63-9. 10. Juran BD, Lazaridis KN. Environmental factors in primary biliary cirrhosis. Semin Liver Dis 2014;34:265-72. 11. Probert PM, Leitch AC, Dunn MP, et al. Identification of a xenobiotic as a potential environmental trigger in primary biliary cholangitis. J Hepatol 2018;69:1123-1135. 12. Gleicher N, Barad DH. Gender as risk factor for autoimmune diseases. J Autoimmun 2007;28:1-6. 13. Smyk DS, Rigopoulou EI, Pares A, et al. Sex differences associated with primary biliary cirrhosis. Clin Dev Immunol 2012;2012:610504. 14. Carbone M, Mells GF, Pells G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology 2013;144:560-569 e7; quiz e13-4. 15. Schwinge D, Schramm C. Sex-related factors in autoimmune liver diseases. Semin Immunopathol 2019;41:165-175. 16. Smith-Bouvier DL, Divekar AA, Sasidhar M, et al. A role for sex chromosome complement in the female bias in autoimmune disease. J Exp Med 2008;205:1099-108. 17. Libert C, Dejager L, Pinheiro I. The X chromosome in immune functions: when a chromosome makes the difference. Nat Rev Immunol 2010;10:594-604. 18. Carrel L, Willard HF. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature 2005;434:400-4. 19. Mitchell MM, Lleo A, Zammataro L, et al. Epigenetic investigation of variably X chromosome inactivated genes in monozygotic female twins discordant for primary biliary cirrhosis. Epigenetics 2011;6:95-102. 20. Invernizzi P, Miozzo M, Battezzati PM, et al. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet 2004;363:533-5. 21. Lleo A, Oertelt-Prigione S, Bianchi I, et al. Y chromosome loss in male patients with primary biliary cirrhosis. J Autoimmun 2013;41:87-91. 22. Lau A, West L, Tullius SG. The Impact of Sex on Alloimmunity. Trends Immunol 2018;39:407-418. 23. Bebo BF, Jr., Fyfe-Johnson A, Adlard K, et al. Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. J Immunol 2001;166:2080-9. 24. Bebo BF, Jr., Schuster JC, Vandenbark AA, et al. Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells. J Immunol 1999;162:35-40. 25. Rettew JA, Huet YM, Marriott I. Estrogens augment cell surface TLR4 expression on murine macrophages and regulate sepsis susceptibility in vivo. Endocrinology 2009;150:3877-84. 26. Rettew JA, Huet-Hudson YM, Marriott I. Testosterone reduces macrophage expression in the mouse of toll-like receptor 4, a trigger for inflammation and innate immunity. Biol Reprod 2008;78:432-7. 27. Xiu F, Anipindi VC, Nguyen PV, et al. High Physiological Concentrations of Progesterone Reverse Estradiol-Mediated Changes in Differentiation and Functions of Bone Marrow Derived Dendritic Cells. PLoS One 2016;11:e0153304. 28. Medina KL, Strasser A, Kincade PW. Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors. Blood 2000;95:2059-67. 29. Rubel LR, Rabin L, Seeff LB, et al. Does primary biliary cirrhosis in men differ from primary biliary cirrhosis in women? Hepatology 1984;4:671-7. 30. Amano K, Leung PS, Rieger R, et al. Chemical xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food additive, 2-octynoic acid. J Immunol 2005;174:5874-83. 31. Rieger R, Leung PS, Jeddeloh MR, et al. Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. J Autoimmun 2006;27:7-16. 32. Corpechot C, Chretien Y, Chazouilleres O, et al. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol 2010;53:162-9. 33. Ingersoll MA. Sex differences shape the response to infectious diseases. PLoS Pathog 2017;13:e1006688. 34. Dwivedi M, Kumar P, Laddha NC, et al. Induction of regulatory T cells: A role for probiotics and prebiotics to suppress autoimmunity. Autoimmun Rev 2016;15:379-92. 35. Skapenko A, Leipe J, Lipsky PE, et al. The role of the T cell in autoimmune inflammation. Arthritis Res Ther 2005;7 Suppl 2:S4-14. 36. Corthay A. How do regulatory T cells work? Scand J Immunol 2009;70:326-36. 37. Shi TY, Zhang FC. Role of autoimmunity in primary biliary cirrhosis. World J Gastroenterol 2012;18:7141-8. 38. Afzali B, Lombardi G, Lechler RI, et al. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007;148:32-46. 39. Takahashi T, Kuniyasu Y, Toda M, et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998;10:1969-80. 40. Thornton AM, Shevach EM. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 2000;164:183-90. 41. Liblau RS, Wong FS, Mars LT, et al. Autoreactive CD8 T cells in organ-specific autoimmunity: emerging targets for therapeutic intervention. Immunity 2002;17:1-6. 42. Lefrancois L, Obar JJ. Once a killer, always a killer: from cytotoxic T cell to memory cell. Immunol Rev 2010;235:206-18. 43. Hersperger AR, Makedonas G, Betts MR. Flow cytometric detection of perforin upregulation in human CD8 T cells. Cytometry A 2008;73:1050-7. 44. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol 2010;28:445-89. 45. Saito S, Nakashima A, Shima T, et al. Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol 2010;63:601-10. 46. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-93. 47. Dardalhon V, Korn T, Kuchroo VK, et al. Role of Th1 and Th17 cells in organ-specific autoimmunity. J Autoimmun 2008;31:252-6. 48. Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708-12. 49. Castellanos MC, Munoz C, Montoya MC, et al. Expression of the leukocyte early activation antigen CD69 is regulated by the transcription factor AP-1. J Immunol 1997;159:5463-73. 50. Lopez-Cabrera M, Santis AG, Fernandez-Ruiz E, et al. Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors. J Exp Med 1993;178:537-47. 51. Stauber DJ, Debler EW, Horton PA, et al. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A 2006;103:2788-93. 52. Poulton TA, Gallagher A, Potts RC, et al. Changes in activation markers and cell membrane receptors on human peripheral blood T lymphocytes during cell cycle progression after PHA stimulation. Immunology 1988;64:419-25. 53. Kumar P, Bhattacharya P, Prabhakar BS. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity. J Autoimmun 2018;95:77-99. 54. Weiner HL, da Cunha AP, Quintana F, et al. Oral tolerance. Immunol Rev 2011;241:241-59. 55. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009;30:636-45. 56. Liston A, Gray DH. Homeostatic control of regulatory T cell diversity. Nat Rev Immunol 2014;14:154-65. 57. Caridade M, Graca L, Ribeiro RM. Mechanisms Underlying CD4+ Treg Immune Regulation in the Adult: From Experiments to Models. Front Immunol 2013;4:378. 58. Shu Y, Hu Q, Long H, et al. Epigenetic Variability of CD4+CD25+ Tregs Contributes to the Pathogenesis of Autoimmune Diseases. Clin Rev Allergy Immunol 2017;52:260-272. 59. Chinen T, Kannan AK, Levine AG, et al. An essential role for the IL-2 receptor in Treg cell function. Nat Immunol 2016;17:1322-1333. 60. Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol 2016;39:98-106. 61. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008;322:271-5. 62. Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009;206:3015-29. 63. Do JS, Visperas A, Sanogo YO, et al. An IL-27/Lag3 axis enhances Foxp3+ regulatory T cell-suppressive function and therapeutic efficacy. Mucosal Immunol 2016;9:137-45. 64. Krams SM, Van de Water J, Coppel RL, et al. Analysis of hepatic T lymphocyte and immunoglobulin deposits in patients with primary biliary cirrhosis. Hepatology 1990;12:306-13. 65. Lan RY, Salunga TL, Tsuneyama K, et al. Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J Autoimmun 2009;32:43-51. 66. Krams SM, Cao S, Hayashi M, et al. Elevations in IFN-gamma, IL-5, and IL-10 in patients with the autoimmune disease primary biliary cirrhosis: association with autoantibodies and soluble CD30. Clin Immunol Immunopathol 1996;80:311-20. 67. Harada K, Van de Water J, Leung PS, et al. In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset. Hepatology 1997;25:791-6. 68. Nagano T, Yamamoto K, Matsumoto S, et al. Cytokine profile in the liver of primary biliary cirrhosis. J Clin Immunol 1999;19:422-7. 69. Tsuda M, Ambrosini YM, Zhang W, et al. Fine phenotypic and functional characterization of effector cluster of differentiation 8 positive T cells in human patients with primary biliary cirrhosis. Hepatology 2011;54:1293-302. 70. Lan RY, Cheng C, Lian ZX, et al. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology 2006;43:729-37. 71. Chen J, Hou X, Jia H, et al. Regulatory T cells with a defect in inhibition on co-stimulation deteriorated primary biliary cholangitis. Oncotarget 2017;8:108406-108417. 72. Wang D, Zhang H, Liang J, et al. CD4+ CD25+ but not CD4+ Foxp3+ T cells as a regulatory subset in primary biliary cirrhosis. Cell Mol Immunol 2010;7:485-90. 73. Penz-Osterreicher M, Osterreicher CH, Trauner M. Fibrosis in autoimmune and cholestatic liver disease. Best Pract Res Clin Gastroenterol 2011;25:245-58. 74. Katsumi T, Tomita K, Leung PS, et al. Animal models of primary biliary cirrhosis. Clin Rev Allergy Immunol 2015;48:142-53. 75. Gerussi A, Cristoferi L, Carbone M, et al. The immunobiology of female predominance in primary biliary cholangitis. J Autoimmun 2018;95:124-132. 76. Rieger R, Gershwin ME. The X and why of xenobiotics in primary biliary cirrhosis. J Autoimmun 2007;28:76-84. 77. Shimoda S, Nakamura M, Ishibashi H, et al. HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. J Exp Med 1995;181:1835-45. 78. Kita H, Matsumura S, He XS, et al. Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J Clin Invest 2002;109:1231-40. 79. Haydon GH, Neuberger J. PBC: an infectious disease? Gut 2000;47:586-8. 80. Odin JA, Huebert RC, Casciola-Rosen L, et al. Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis. J Clin Invest 2001;108:223-32. 81. Mao TK, Davis PA, Odin JA, et al. Sidechain biology and the immunogenicity of PDC-E2, the major autoantigen of primary biliary cirrhosis. Hepatology 2004;40:1241-8. 82. Wakabayashi K, Lian ZX, Leung PS, et al. Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology 2008;48:531-40. 83. Hsueh YH, Chang YN, Loh CE, et al. AAV-IL-22 modifies liver chemokine activity and ameliorates portal inflammation in murine autoimmune cholangitis. J Autoimmun 2016;66:89-97. 84. Oertelt S, Lian ZX, Cheng CM, et al. Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol 2006;177:1655-60. 85. Yang GX, Lian ZX, Chuang YH, et al. Adoptive transfer of CD8(+) T cells from transforming growth factor beta receptor type II (dominant negative form) induces autoimmune cholangitis in mice. Hepatology 2008;47:1974-82. 86. Zhang W, Sharma R, Ju ST, et al. Deficiency in regulatory T cells results in development of antimitochondrial antibodies and autoimmune cholangitis. Hepatology 2009;49:545-52. 87. Wakabayashi K, Lian ZX, Moritoki Y, et al. IL-2 receptor alpha(-/-) mice and the development of primary biliary cirrhosis. Hepatology 2006;44:1240-9. 88. Chang CH, Chen YC, Zhang W, et al. Innate immunity drives the initiation of a murine model of primary biliary cirrhosis. PLoS One 2015;10:e0121320. 89. Syu BJ, Loh CE, Hsueh YH, et al. Dual Roles of IFN-gamma and IL-4 in the Natural History of Murine Autoimmune Cholangitis: IL-30 and Implications for Precision Medicine. Sci Rep 2016;6:34884. 90. Fontenot JD, Rasmussen JP, Williams LM, et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005;22:329-41. 91. Baiocchini A, Montaldo C, Conigliaro A, et al. Extracellular Matrix Molecular Remodeling in Human Liver Fibrosis Evolution. PLoS One 2016;11:e0151736. 92. Nagler-Anderson C, Bhan AK, Podolsky DK, et al. Control freaks: immune regulatory cells. Nat Immunol 2004;5:119-22. 93. Khalil N. TGF-beta: from latent to active. Microbes and Infection 1999;1:1255-1263. 94. Oo YH, Adams DH. The role of chemokines in the recruitment of lymphocytes to the liver. J Autoimmun 2010;34:45-54. 95. Bae HR, Leung PS, Tsuneyama K, et al. Chronic expression of interferon-gamma leads to murine autoimmune cholangitis with a female predominance. Hepatology 2016;64:1189-201. 96. Yang GX, Wu Y, Tsukamoto H, et al. CD8 T cells mediate direct biliary ductule damage in nonobese diabetic autoimmune biliary disease. J Immunol 2011;186:1259-67. 97. Harada K, Nakanuma Y. Molecular mechanisms of cholangiopathy in primary biliary cirrhosis. Med Mol Morphol 2006;39:55-61. 98. Yoshida K, Yang GX, Zhang W, et al. Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice. Hepatology 2009;50:1494-500. 99. Chuang YH, Lian ZX, Cheng CM, et al. Increased levels of chemokine receptor CXCR3 and chemokines IP-10 and MIG in patients with primary biliary cirrhosis and their first degree relatives. J Autoimmun 2005;25:126-32. 100. Ma HD, Ma WT, Liu QZ, et al. Chemokine receptor CXCR3 deficiency exacerbates murine autoimmune cholangitis by promoting pathogenic CD8(+) T cell activation. J Autoimmun 2017;78:19-28. 101. Zhang W, Fei Y, Gao J, et al. The role of CXCR3 in the induction of primary biliary cirrhosis. Clin Dev Immunol 2011;2011:564062. 102. Liu QZ, Ma WT, Yang JB, et al. The CXC Chemokine Receptor 3 Inhibits Autoimmune Cholangitis via CD8(+) T Cells but Promotes Colitis via CD4(+) T Cells. Front Immunol 2018;9:1090. 103. Groom JR, Luster AD. CXCR3 in T cell function. Exp Cell Res 2011;317:620-31. 104. Lacotte S, Brun S, Muller S, et al. CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci 2009;1173:310-7. 105. Kwak HB, Ha H, Kim HN, et al. Reciprocal cross-talk between RANKL and interferon-gamma-inducible protein 10 is responsible for bone-erosive experimental arthritis. Arthritis Rheum 2008;58:1332-42. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72867 | - |
dc.description.abstract | 原發性膽汁性膽管炎(primary biliary cholangitis; PBC)為一好發於女性的慢性肝臟自體免疫疾病,發病機率女比男約為10:1,目前對於PBC好發於女性的機制仍不清楚。免疫系統能維持著免疫耐受性的狀態,是因為促進發炎的effector T cells (Teff)和抑制免疫反應的regulatory T cells (Tregs)維持著平衡,但是當Teff或Tregs細胞數目改變或者功能缺失時,造成Teff發炎反應過強,便會導致自體免疫疾病。本篇研究推測PBC好發於女性可能為疾病初期時Teff與Tregs在性別間失衡程度不同所導致,因此運用2-OA-OVA-induced PBC小鼠模式,分別致敏C57BL/6的公母鼠,探討小鼠在相同基因與環境的情況下,性別的不同是否會影響PBC的疾病嚴重程度,並研究肝臟中Teff或Tregs的平衡。我們發現病程嚴重時期的PBC小鼠,母鼠肝臟的免疫細胞浸潤、發炎與纖維化情況顯著比公鼠嚴重,確認2-OA-OVA-induced PBC小鼠模式具有性別差異。在疾病初期,母鼠肝臟的免疫細胞浸潤、發炎情況也比公鼠嚴重。其中,母鼠CD8+ Teff比例顯著高於公鼠,CD4+ Teff與Foxp3+ Tregs的比例則沒有統計上的差異。功能方面,CD8+ T cells在性別間活化、分化以及分泌的功能都沒有差異,不過公鼠的CD4+ Teff較母鼠更加活化與耗竭、公鼠的Foxp3+ Tregs則表現比母鼠更高比例的免疫抑制功能相關蛋白。我們也發現母鼠肝臟CXCL9與CXCL10的表現量顯著高於公鼠,於是推測母鼠肝臟有大量免疫細胞浸潤是受到chemokine的招募,但在分析肝臟中各種免疫細胞CXCR3 (CXCL9與CXCL10的receptor)的表現量後,發現母鼠免疫細胞上CXCR3表現量並沒有顯著高於公鼠。本篇研究發現2-OA-OVA-induced PBC小鼠模式具有母鼠疾病較嚴重的性別差異,而此差異可能由疾病初期時,性別間Teff與Tregs之間的失衡程度不同所導致。 | zh_TW |
dc.description.abstract | Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease which caused by inflammation targeting intrahepatic small bile ducts. A sex disparity happens in PBC with a female-to-male ratio of 10:1. However, the reason why females outnumber males remains unclear. In this study, we investigated whether the female-predominant effect of PBC results from female and male experience different immune responses in the initiation of PBC by using the xenobiotic-induced PBC murine model. Our results showed that the female PBC mice expressed more exacerbating liver inflammation and cell infiltration than the male PBC mice in the initiation of diseases. The percentage of liver CD8+ T cells was increased in female PBC mice, while effector CD4+ T cells and Foxp3+ regulatory cells were comparable. Although the two groups exhibited parallel functions of CD8+ T cells, CD4+ Teff expressed more activation and inhibition markers, and Foxp3+ Tregs expressed more suppression-maintaining markers in the male PBC mice.CXCL9 and CXCL10, which play crucial roles in trafficking infiltrating cells, expressed higher levels in the liver of female PBC mice. However, there were no differences between the chemokines receptor, CXCR3, between the two groups. In summary, our data indicated that the female mice exhibited more effector immune response might result from an imbalance of Teff/ Tregs in the initiation of PBC. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T07:08:37Z (GMT). No. of bitstreams: 1 ntu-108-R06424021-1.pdf: 2504656 bytes, checksum: ccbdf209d634f9d6a3cbf2d1d60a263c (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 誌謝…………………………………………………………………………...………….i
摘要…………………………………………………………………………...………....ii Abstract……...………………………………………………………………………….iii Abbreviation………………………………………………………………….…………iv Content………………………………………………..………………………………...vi Content of Figures…………………………………………..………………………....viii Content of Tables ……………………….…………………..…………………………...ix Chapter 1. Introduction………………………………..…………………………………1 1.1 Primary biliary cholangitis……………………..…………………….…2 1.2 The female predominance in PBC………………………………3 1.3 T cell homeostasis in autoimmune diseases…………………4 1.3.1. Effector CD8+ and CD4+ T cells in autoimmune diseases…….5 1.3.2. Regulatory T cells in autoimmune diseases………………………………6 1.3.3. T cells homeostasis in PBC…………………………………….…………6 1.4 PBC mouse models…………………………………….……………………….7 1.4.1. Molecular mimicry……………………………….………………………7 1.4.2. Xenobiotic-induced PBC mouse model……………………………….…8 1.4.3. T cell homeostasis in PBC mouse model……………………………8 Specific aim……………………………….………………………………………10 Chapter 2. Material and Methods………………….……………………………………11 2.1 Mice……………………………….………………………………………..…12 2.2 Xenobiotic 2-OA-OVA-induced PBC model………………………………….12 2.3 Serum anti-PDC-E2 IgM and IgG measurement…………………………12 2.4 Liver perfusion and samples preparation……………………………13 2.5 Histopathology………………………………..……………………………….13 2.6 Liver RNA extraction, complementary DNA synthesis, and quantitative real-time PCR……………..……………………………………………14 2.7 Liver mononuclear cells (MNCs) isolation……………………………14 2.8 LAP detection………………………………………….………………………14 2.9 Cell surface staining………………………………….……………………..…15 2.10 Intracellular cytokine detection………………………………….……….15 2.11 Intracellular staining (ICS) ………………………………….……………….15 2.12 Flow cytometry analysis………………………………….…………………..16 2.13 Statistical analysis………………………………….………………………...16 Chapter 3. Results………………………………….…………………………………...17 3.1 Female mice exhibited more exacerbating liver fibrosis and inflammation at eleven weeks post-immunization..….…18 3.2 Female mice had higher immune responses in the liver at five weeks post-immunization..………………………………….…………………19 3.3 Female and male PBC mice had parallel functions of effector CD8+ T cells.......19 3.4 Effector CD4+ T cells expressed more activation and inhibition markers in the male PBC mice. ……………………………………20 3.5 Foxp3+ Tregs of male PBC mice had higher suppression proteins expression. …21 3.6 Female mice had higher levels of CXCL9 and CXCL10 in liver homogenate. ..... 21 Chapter 4. Discussion………………………………….………………………………..23 References………………………………….…………………………………………..28 Tables....………………………………………………..………..……………………...36 Figures………………………………….………………………………………………39 | |
dc.language.iso | en | |
dc.title | 探討雄性和雌性小鼠在原發性膽汁性膽管炎初期的肝臟免疫反應 | zh_TW |
dc.title | Investigation of liver immune responses of males and females in the initiation of primary biliary cholangitis | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陶秘華(Mi-Hua Tao),楊宏志(Hung-Chih Yang),李岳倫(Yueh-Lun Lee) | |
dc.subject.keyword | 原發性膽汁性膽管炎,性別差異,免疫失衡,effector T cells,regulatory T cells,chemokine, | zh_TW |
dc.subject.keyword | primary biliary cholangitis,sex disparity,effector T cells,regulatory T cells,chemokine, | en |
dc.relation.page | 51 | |
dc.identifier.doi | 10.6342/NTU201901833 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-07-23 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 醫學檢驗暨生物技術學研究所 | zh_TW |
顯示於系所單位: | 醫學檢驗暨生物技術學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 2.45 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。